

Cheryl A London

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1707275/publications.pdf>

Version: 2024-02-01

57
papers

3,033
citations

185998

28
h-index

155451

55
g-index

59
all docs

59
docs citations

59
times ranked

2805
citing authors

#	ARTICLE	IF	CITATIONS
1	VEGF Receptor Inhibitor-Induced Hypertension: Emerging Mechanisms and Clinical Implications. <i>Current Oncology Reports</i> , 2022, 24, 463-474.	1.8	28
2	A CTSA One Health Alliance (COHA) survey of clinical trial infrastructure in North American veterinary institutions. <i>BMC Veterinary Research</i> , 2021, 17, 90.	0.7	2
3	Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task Force. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29188.	0.8	7
4	Improving Cancer Drug Discovery by Studying Cancer across the Tree of Life. <i>Molecular Biology and Evolution</i> , 2020, 37, 11-17.	3.5	20
5	Identification of Genetic Susceptibility Factors Associated with Canine Gastric Dilatation-Volvulus. <i>Genes</i> , 2020, 11, 1313.	1.0	6
6	Safety and toxicity of combined oclacitinib and carboplatin or doxorubicin in dogs with solid tumors: a pilot study. <i>BMC Veterinary Research</i> , 2019, 15, 291.	0.7	3
7	Canine osteosarcoma genome sequencing identifies recurrent mutations in DMD and the histone methyltransferase gene SETD2. <i>Communications Biology</i> , 2019, 2, 266.	2.0	77
8	Targeted Therapies in Veterinary Oncology. <i>Veterinary Clinics of North America - Small Animal Practice</i> , 2019, 49, 917-931.	0.5	12
9	Leveraging dogs with spontaneous cancer to advance drug development. , 2019, , 343-372.		0
10	Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON. <i>Cancer Immunology Research</i> , 2018, 6, 671-684.	1.6	29
11	Comparative oncology DNA sequencing of canine T cell lymphoma via human hotspot panel. <i>Oncotarget</i> , 2018, 9, 22693-22702.	0.8	18
12	Plasma cytokeratinâ€18 concentrations as noninvasive biomarker of early gastrointestinal toxicosis in dogs receiving toceranib. <i>Journal of Veterinary Internal Medicine</i> , 2018, 32, 2061-2068.	0.6	2
13	Consecutive Day HSP90 Inhibitor Administration Improves Efficacy in Murine Models of KIT-Driven Malignancies and Canine Mast Cell Tumors. <i>Clinical Cancer Research</i> , 2018, 24, 6396-6407.	3.2	10
14	Classical NF-ÎB Metabolically Reprograms Sarcoma Cells Through Regulation of Hexokinase 2. <i>Frontiers in Oncology</i> , 2018, 8, 104.	1.3	49
15	Phase I/II evaluation of RV1001, a novel PI3KÎ inhibitor, in spontaneous canine lymphoma. <i>PLoS ONE</i> , 2018, 13, e0195357.	1.1	15
16	Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma. <i>BMC Veterinary Research</i> , 2018, 14, 250.	0.7	23
17	MiR-34a regulates the invasive capacity of canine osteosarcoma cell lines. <i>PLoS ONE</i> , 2018, 13, e0190086.	1.1	27
18	Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis. <i>BMC Cancer</i> , 2017, 17, 67.	1.1	39

#	ARTICLE	IF	CITATIONS
19	Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma. PLoS ONE, 2017, 12, e0181885.	1.1	16
20	Safety and efficacy of targeted hyperthermia treatment utilizing gold nanorod therapy in spontaneous canine neoplasia. BMC Veterinary Research, 2017, 13, 294.	0.7	12
21	Comparison of harmonic blade versus traditional approach in canine patients undergoing spinal decompressive surgery for naturally occurring thoracolumbar disk extrusion. PLoS ONE, 2017, 12, e0172822.	1.1	2
22	Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma. PLoS ONE, 2016, 11, e0159607.	1.1	49
23	Mir-9 is overexpressed in spontaneous canine osteosarcoma and promotes a metastatic phenotype including invasion and migration in osteoblasts and osteosarcoma cell lines. BMC Cancer, 2016, 16, 784.	1.1	32
24	Perspectives from man's best friend: National Academy of Medicine's Workshop on Comparative Oncology. Science Translational Medicine, 2016, 8, 324ps5.	5.8	108
25	The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma. Molecular Cancer Therapeutics, 2016, 15, 1018-1028.	1.9	75
26	Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study. PLoS ONE, 2015, 10, e0124889.	1.1	51
27	Human Genetic Relevance and Potent Antitumor Activity of Heat Shock Protein 90 Inhibition in Canine Lung Adenocarcinoma Cell Lines. PLoS ONE, 2015, 10, e0142007.	1.1	13
28	Characterization of STAT3 expression, signaling and inhibition in feline oral squamous cell carcinoma. BMC Veterinary Research, 2015, 11, 206.	0.7	26
29	Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma. BMC Veterinary Research, 2015, 11, 131.	0.7	36
30	Abstract 4700: The novel and selective PI3K γ inhibitor, RV1001, displays single agent biologic activity in spontaneous canine NHL. , 2015, , .		1
31	The effects of preoperative oral administration of carprofen or tramadol on postoperative analgesia in dogs undergoing cutaneous tumor removal. Canadian Veterinary Journal, 2015, 56, 817-22.	0.0	11
32	Preclinical Evaluation of the Novel, Orally Bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in Spontaneous Canine Cancer: Results of a Phase I Study. PLoS ONE, 2014, 9, e87585.	1.1	79
33	Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines. BMC Veterinary Research, 2014, 10, 160.	0.7	17
34	Kinase dysfunction and kinase inhibitors. Veterinary Dermatology, 2013, 24, 181.	0.4	17
35	Biologic activity of the novel small molecule STAT3 inhibitor LLL12 against canine osteosarcoma cell lines. BMC Veterinary Research, 2012, 8, 244.	0.7	21
36	Phase I Evaluation of STA-1474, a Prodrug of the Novel HSP90 Inhibitor Ganetespib, in Dogs with Spontaneous Cancer. PLoS ONE, 2011, 6, e27018.	1.1	40

#	ARTICLE	IF	CITATIONS
37	Characterization and modulation of canine mast cell derived eicosanoids. <i>Veterinary Immunology and Immunopathology</i> , 2010, 135, 118-127.	0.5	12
38	Multi-center, Placebo-controlled, Double-blind, Randomized Study of Oral Toceranib Phosphate (SU11654), a Receptor Tyrosine Kinase Inhibitor, for the Treatment of Dogs with Recurrent (Either Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 3856-3865.	3.2	331
39	Characterization of STAT3 activation and expression in canine and human osteosarcoma. <i>BMC Cancer</i> , 2009, 9, 81.	1.1	98
40	The novel HSP90 inhibitor STA-9090 exhibits biologic activity against osteosarcoma cell lines. <i>International Journal of Cancer</i> , 2009, 125, 2792-2801.	2.3	73
41	Tyrosine Kinase Inhibitors in Veterinary Medicine. <i>Topics in Companion Animal Medicine</i> , 2009, 24, 106-112.	0.4	125
42	The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors. <i>Experimental Hematology</i> , 2008, 36, 1266-1277.	0.2	103
43	The Role of Small Molecule Inhibitors for Veterinary Patients. <i>Veterinary Clinics of North America - Small Animal Practice</i> , 2007, 37, 1121-1136.	0.5	1
44	Comparison of COAP and UW-19 Protocols for Dogs with Multicentric Lymphoma. <i>Journal of Veterinary Internal Medicine</i> , 2007, 21, 1355-1363.	0.6	78
45	Comparison of Thoracic Radiographs and Single Breath-Hold Helical CT for Detection of Pulmonary Nodules in Dogs with Metastatic Neoplasia. <i>Journal of Veterinary Internal Medicine</i> , 2006, 20, 508-515.	0.6	140
46	Use of Kit Internal Tandem Duplications to Establish Mast Cell Tumor Clonality in 2 Dogs. <i>Journal of Veterinary Internal Medicine</i> , 2004, 18, 915-917.	0.6	23
47	Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. <i>Clinical Cancer Research</i> , 2003, 9, 2755-68.	3.2	212
48	Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors. <i>Clinical Cancer Research</i> , 2003, 9, 5729-34.	3.2	91
49	Prevalence and importance of internal tandem duplications in exons 11 and 12 of c-kit in mast cell tumors of dogs. <i>American Journal of Veterinary Research</i> , 2002, 63, 1718-1723.	0.3	130
50	Evaluation of a Discontinuous Treatment Protocol (VELCAP-S) for Canine Lymphoma. <i>Journal of Veterinary Internal Medicine</i> , 2001, 15, 348-354.	0.6	90
51	Evaluation of a Discontinuous Treatment Protocol (VELCAP-S) for Canine Lymphoma. <i>Journal of Veterinary Internal Medicine</i> , 2001, 15, 348.	0.6	12
52	Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. <i>Experimental Hematology</i> , 1999, 27, 689-697.	0.2	203
53	Lomustine (CCNU) for the Treatment of Resistant Lymphoma in Dogs. <i>Journal of Veterinary Internal Medicine</i> , 1999, 13, 395-398.	0.6	116
54	Treatment of Canine Mast Cell Tumors with CCNU (Lomustine). <i>Journal of Veterinary Internal Medicine</i> , 1999, 13, 601-605.	0.6	120

#	ARTICLE	IF	CITATIONS
55	Lomustine (CCNU) for the treatment of resistant lymphoma in dogs. <i>Journal of Veterinary Internal Medicine</i> , 1999, 13, 395-8.	0.6	40
56	Treatment of canine mast cell tumors with CCNU (lomustine). <i>Journal of Veterinary Internal Medicine</i> , 1999, 13, 601-5.	0.6	56
57	Characterizing the metabolic role of STAT3 in canine osteosarcoma. <i>Veterinary and Comparative Oncology</i> , 0, , .	0.8	1